## Abstracts

### 223

**SERUM 25-HYDROXYVITAMIN D3 LEVELS AND CLINICAL COURSE OF SYSTEMIC LUPUS ERYTHEMATOSUS: A CROSS SECTIONAL RETROSPECTIVE COHORT STUDY IN A REFERRAL CENTRE**

M Mohd Noh1, DM Suahilai1, NS Shahril1, S Akas2, University Malaysia Sabah, Faculty of Medicine and Allied Health Sciences, Kajang, Malaysia; 3Hospital Putrajaya, Medicine, Putrajaya, Malaysia; 4Hospital Putrajaya, Medical, Putrajaya, Malaysia

**Background and aims** To study the association between serum 25-Hydroxyvitamin D3 levels and clinical manifestations, disease activity, and disease damage of systemic lupus erythematosus (SLE).

**Methods** This was a retrospective cross sectional study of SLE patients seen between 1996 until 2015. Patients were grouped according to the Vitamin D3 levels: group 1 (<25 nmol/L: deficiency), group 2 (25–75 nmol/L: insufficiency) and group 3 (>75 nmol/L: adequate). Assessment of disease activity was done using Systemic Lupus Erythematosus Disease Activity Index Selena Modification (SLEDAI) while Systemic Lupus International Collaborating Clinics (SLICC) was use for disease damage.

**Results** A total of 42 patients had their serum 25-Hydroxyvitamin D3 levels taken at one point of their visit. Majority were females (n=41). Mean age was 37.2 years (SD ±13.13) and mean duration of illness 9.5 years (SD ±5.7). The proportion of patients with 25-Hydroxyvitamin D3 level group 1 was 31%, group 2 was 61.9% and group 3 was 7.1% respectively. Main clinical manifestations were haematological 71.1%, arthritis 68.9%, malar rash 53.3%. SLEDAI mild activity (0-3) 90.5%, moderate activity (4-8) was 4.8% and severe activity (9-10) was 4.8%. SLICC showed 78.6% had no damage and 21.4% with damage. Test of association using ANOVA, did not show any significant difference between Vitamin D3 level and SLEDAI, SLICC and clinical manifestations were observed among the group.

**Conclusions** Vitamin D insufficiency and deficiency was common in our SLE cohort. However, we did not find significant association between vitamin D deficiency and disease activity, damage or clinical manifestations. The study limitation includes small number of patients and retrospective design.

### 224

**PROTEIN-LOSING ENTEROPATHY AND FULMINANT INTESTINAL VASCULITIS IN A FILIPINO LUPUS PATIENT: A CASE REPORT**

RM Molina, S Navarra. University of Santo Tomas, Internal Medicine- Section of Rheumatology, Metro Manila, Philippines

**Background and aims** We describe a rare case of GI vasculitis flare in SLE presenting as diarrhoea, hematochezia and profound hypoalbuminemia.

**Methods** Case report

**Results** A 49 year old patient has had stable SLE in the past 22 years until she developed episodes of diffuse abdominal pains accompanied by alternating diarrhoea with constipation for 12 months; colonoscopy showed rectal ulcers and abdomi- nal CT scan showed colonic diverticulosis. She received supportive therapy with only minimal relief. She was first admitted due to severe abdominal pain and worsening diarrhoea; laboratory tests disclosed thrombocytopenia, hypocomplementemia and high titer anti-dsDNA; there was dramatic resolution of symptoms with high dose corticosteroid and she was discharged significantly improved. A few weeks later while on tapering prednisone, she was re-admitted because of recurrence of profuse diarrhoea with severe electrolyte imbalance. Hospital course was marked by diarrhoea, severe hypoalbuminemia with progressive anasarca requiring intravenous albumin infusions, and episodes of massive hematochezia requiring multiple blood transfusions. Colonoscopy showed ischaemic colitis with edematous friable recto-sigmoid mucosa. Intravenous corticosteroid was increased. She underwent abdomino-perineal resection with ileal resection of necrotic intestinal segments; histopath confirmed haemorrhagic gangrenous necrosis of the small intestine and colon, with small and medium vessel vasculitis and thrombosis. Although immediate post-operative course was uneventful, she succumbed a few days later to fulminant bacterial peritonitis due to anastomotic failure with extension of the bowel ischemia.

**Conclusions** This case illustrates the diagnostic dilemma and management challenges of lupus mesenteric vasculitis, requiring intensive monitoring for complications with aggressive supportive and disease-specific measures.

### 225

**GASTROINTESTINAL FLARES AMONG FILIPINO PATIENTS WITH SLE: A CASE SERIES**

RM Molina*. S Navarra. University of Santo Tomas, Internal Medicine- Section of Rheumatology, Metro Manila, Philippines

**Background and aims** Gastrointestinal (GI) involvement in SLE ranges from 2.2%–9.7%, and nonspecific manifestations pose a diagnostic challenge. This series describes characteristics, treatment and outcomes of patients with GI involvement as the primary manifestation of SLE activity.

**Methods** Case series of 10 Filipino SLE patients with proven GI flares, seen at the Lupus Clinics of University of Santo Tomas (UST) Hospital, Manila, Philippines.

**Results** All 10 patients were females with mean age 31.7±9.35 SD (19 - 49) and disease duration 6.08±7.34 SD (0 - 22) years. Most common GI manifestations were abdominal pain (100%), ileus (60%), vomiting (50%) and diarrhoea (40%). Extra-intestinal manifestations included malar rash (70%), arthritis (60%),
hypocomplementemia (60%), alopecia (50%), and hemolytic anemia (40%). All patients showed significant initial response to high dose corticosteroid. Three patients eventually required surgery including ileal resection, abdomino-perineal resection and appendectomy; post-op histopath findings confirmed vasculitis in all 3 patients. One patient with ileal ischemia and perforation requiring resection also received belimumab infusions which enabled successful tapering and discontinuation of steroid. Another patient with refractory protein losing enteropathy and ischaemic colitis underwent abdomino-perineal with ileal resection, but succumbed to anastomotic failure with fulminant bacterial peritonitis.

Conclusions Though rare, gastrointestinal flare in SLE can be potentially catastrophic. Because of nonspecific manifestations, diagnosis strongly relies on clinical assumption and response to steroids. In some cases, surgery can be life-saving and belimumab offers another effective therapeutic option.

Background and aims The aim of this study was to review renal flare frequency, to identify potential risk factors for relapses, to assess the value of serological tests during flares and to analyse their impact of global outcome in lupus nephritis (LN) patients.

Methods Patients with biopsy proven LN were identified from our database. LN classes were defined according to the ISN/RPS classification. According to the response to treatment, LN patients were divided into 3 groups of complete remission (CR), partial remission (PR) and no response (NR). Those in remission were divided into 2 groups of relapsing and non-relapsing during maintenance period.

Results 218 (70.64%) of 276 SLE patients with biopsy proven LN (class I-18 patients, class II-45, class III-56, class IV-75, class V-54, class VI-2, mixed forms - 26) achieved either CR (55.8%) or PR (23.2%). 47 patients had one flare, 36 - two, 27 - three, 17 - four flares. The maintenance immunomodulating drugs at the time of flare was low dose corticosteroids and/or azathioprine. Non-adherence to treatment at time of relapse was documented in 26 patients.

Conclusions Renal flares in patients with LN are common, have a negative impact on outcome, but cannot be readily predicted. Our study shows that 58.83% of LN patients develop at least one relapse after reaching remission, usually within 2 years. The length of time to flare tends to be shorter in cases of preceding PR than in CR. Lack of adherence to long term immunosuppression was identified as a significant factor in LN flare (20.47%).

Abstract 225 Table 1 Disease characteristics, treatment and outcome of 10 SLE patients with GI manifestations

<table>
<thead>
<tr>
<th>Age</th>
<th>Gastrointestinal manifestations or involvement</th>
<th>Treatment</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>34</td>
<td>Abdominal pain, nausea, vomiting, diarrhea</td>
<td>Dexamethasone</td>
<td>Improved</td>
</tr>
<tr>
<td>33</td>
<td>Recurrent abdominal pain, abdominal tenderness, atrophic gastritis, appendicitis</td>
<td>Methylprednisolone, cyclophosphamide, explor lap with appendectomy</td>
<td>Improved</td>
</tr>
<tr>
<td>45</td>
<td>Epigastric pain, abdominal tenderness, ileus with bowel dilatation</td>
<td>Dexamethasone</td>
<td>Improved</td>
</tr>
<tr>
<td>49</td>
<td>Abdominal pain, diarrhea, hematochezia, ileus, “double halo” sign by CT scan, rectal ulcers, necrotic rectosigmoid</td>
<td>Hydrocortisone, dexamethasone, abdominoperineal with ileal resection</td>
<td>Died</td>
</tr>
<tr>
<td>25</td>
<td>Abdominal pain, vomiting, ileus</td>
<td>Hydrocortisone</td>
<td>Improved</td>
</tr>
<tr>
<td>33</td>
<td>Abdominal pain, nausea, vomiting, ileus</td>
<td>Methylprednisolone</td>
<td>Improved</td>
</tr>
<tr>
<td>27</td>
<td>Abdominal pain, diarrhea</td>
<td>Hydrocortisone, dexamethasone</td>
<td>Improved</td>
</tr>
<tr>
<td>19</td>
<td>Abdominal pain, vomiting, ileus, “double halo” and “comb” sign by CT scan</td>
<td>Methylprednisolone</td>
<td>Improved</td>
</tr>
<tr>
<td>24</td>
<td>Abdominal pain, diarrhea, mucosal inflammation, pneunoperitoneum, by CT scan, ileal perforation</td>
<td>Methylprednisolone, belimumab, ileal resection</td>
<td>Improved</td>
</tr>
<tr>
<td>28</td>
<td>Abdominal pain, ileus, ascites, diffuse enterocolitis with pancreatitis by CT scan</td>
<td>Methylprednisolone, cyclophosphamide</td>
<td>Improved</td>
</tr>
</tbody>
</table>

226 RELAPSES OF LUPUS NEPHRITIS – RISK FACTORS, INCIDENCE AND IMPACT OF OUTCOME

1D Monova, 2S Monov*. 1Medical University – Sofia- Medical Institute, Department of Internal Diseases, Sofia, Bulgaria; 2Medical University – Sofia, Department of Internal Diseases- Clinic of Rheumatology, Sofia, Bulgaria

10.1136/lupus-2017-000215.226